PE20220387A1 - Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer - Google Patents
Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancerInfo
- Publication number
- PE20220387A1 PE20220387A1 PE2021001990A PE2021001990A PE20220387A1 PE 20220387 A1 PE20220387 A1 PE 20220387A1 PE 2021001990 A PE2021001990 A PE 2021001990A PE 2021001990 A PE2021001990 A PE 2021001990A PE 20220387 A1 PE20220387 A1 PE 20220387A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cancer
- treatment
- methods
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 abstract 2
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 102000007357 Methionine adenosyltransferase Human genes 0.000 abstract 1
- 108010007784 Methionine adenosyltransferase Proteins 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 substituted Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripcion proporciona compuestos de acuerdo con la formula I, formula II, y sus sales, tautomeros y/o isotopologos farmaceuticamente aceptables como se describe en la descripcion. Donde en la formula (I), X1 es N o CR5; L es O o NR; R1 selecciona de C1-C6-alquilo, C2-C6-alquenilo, C3-C5-carbociclilo, entre otros; R2 y R3 se seleccionan independientemente de C6-C10-arilo y heteroarilo de 5 a 10 miembros; R4 se selecciona de H, C1-C6-alquilo, C1-C6-alcoxi, entre otros; R6 se selecciona del grupo que consiste en H, C1-C6-alquilo opcionalmente sustituido, -O(C1-C6-alquilo) opcionalmente sustituido, entre otros. Dichos compuestos son inhibidores de la metionina adenosiltransferasa isoforma 2A (MAT2A). Tambien proporcionan composiciones farmaceuticas y metodos para usar los compuestos para el tratamiento del cancer, incluidos algunos canceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855395P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/035036 WO2020243376A1 (en) | 2019-05-31 | 2020-05-29 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220387A1 true PE20220387A1 (es) | 2022-03-18 |
Family
ID=72179154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001990A PE20220387A1 (es) | 2019-05-31 | 2020-05-29 | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220251081A1 (es) |
| EP (1) | EP3976611A1 (es) |
| JP (1) | JP2022534989A (es) |
| AR (1) | AR119046A1 (es) |
| AU (1) | AU2020284018A1 (es) |
| BR (1) | BR112021023825A2 (es) |
| CA (1) | CA3142340A1 (es) |
| CO (1) | CO2021017981A2 (es) |
| CR (1) | CR20210670A (es) |
| IL (1) | IL288395A (es) |
| JO (1) | JOP20210317A1 (es) |
| MA (1) | MA56050A (es) |
| PE (1) | PE20220387A1 (es) |
| SG (1) | SG11202112952SA (es) |
| TW (1) | TW202110841A (es) |
| WO (1) | WO2020243376A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54608B1 (fr) * | 2018-12-27 | 2023-02-28 | Servier Lab | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115960099A (zh) * | 2020-09-24 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CN114507231B (zh) * | 2020-11-17 | 2025-06-03 | 南京再明医药有限公司 | 内酰胺类化合物及其制备方法 |
| AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| WO2022143864A1 (zh) * | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN117295734A (zh) * | 2021-04-30 | 2023-12-26 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| WO2023066283A1 (en) | 2021-10-20 | 2023-04-27 | Insilico Medicine Ip Limited | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof |
| CN118265700A (zh) * | 2021-11-09 | 2024-06-28 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| US20250186444A1 (en) * | 2021-12-21 | 2025-06-12 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Methionine adenosyltransferase 2a heterocyclic inhibitor |
| KR20240138099A (ko) * | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| TW202342024A (zh) * | 2022-03-11 | 2023-11-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用 |
| CA3258709A1 (en) | 2022-06-27 | 2025-03-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | TRICYCLIC COMPOUNDS AND THEIR USES |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| WO2024080788A1 (ko) * | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| CN116239541B (zh) * | 2023-05-11 | 2023-07-21 | 英矽智能科技(上海)有限公司 | N-苯基-2-氧代喹唑啉类化合物及其应用 |
| WO2024255802A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| WO2025152991A1 (zh) * | 2024-01-15 | 2025-07-24 | 江苏威凯尔医药科技股份有限公司 | 一种mat2a抑制剂及其用途 |
| WO2025162209A1 (zh) * | 2024-02-01 | 2025-08-07 | 艾立康药业股份有限公司 | 一种吡啶并吡啶酮类mat2a抑制剂及其药物组合物、医药用途 |
| CN118724899B (zh) * | 2024-07-03 | 2025-09-30 | 中国药科大学 | 2(1h)-喹喔啉酮化合物、其药物组合物及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| EP1315726A1 (en) * | 2000-08-31 | 2003-06-04 | F. Hoffmann-La Roche Ag | 7- oxo pyridopyrimidines as inhibitors of cellular proliferation |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2008078249A1 (en) * | 2006-12-21 | 2008-07-03 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
| JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｊａｎｕｓキナーゼの阻害剤 |
| MX2020010005A (es) * | 2018-03-30 | 2020-10-14 | Agios Pharmaceuticals Inc | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer. |
-
2020
- 2020-05-29 BR BR112021023825A patent/BR112021023825A2/pt not_active Application Discontinuation
- 2020-05-29 US US17/615,255 patent/US20220251081A1/en not_active Abandoned
- 2020-05-29 JP JP2021570897A patent/JP2022534989A/ja active Pending
- 2020-05-29 EP EP20760599.9A patent/EP3976611A1/en not_active Withdrawn
- 2020-05-29 CA CA3142340A patent/CA3142340A1/en not_active Abandoned
- 2020-05-29 SG SG11202112952SA patent/SG11202112952SA/en unknown
- 2020-05-29 WO PCT/US2020/035036 patent/WO2020243376A1/en not_active Ceased
- 2020-05-29 PE PE2021001990A patent/PE20220387A1/es unknown
- 2020-05-29 AR ARP200101527A patent/AR119046A1/es not_active Application Discontinuation
- 2020-05-29 MA MA056050A patent/MA56050A/fr unknown
- 2020-05-29 TW TW109117971A patent/TW202110841A/zh unknown
- 2020-05-29 CR CR20210670A patent/CR20210670A/es unknown
- 2020-05-29 JO JOP/2021/0317A patent/JOP20210317A1/ar unknown
- 2020-05-29 AU AU2020284018A patent/AU2020284018A1/en not_active Abandoned
-
2021
- 2021-11-25 IL IL288395A patent/IL288395A/en unknown
- 2021-12-28 CO CONC2021/0017981A patent/CO2021017981A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR119046A1 (es) | 2021-11-17 |
| AU2020284018A1 (en) | 2022-01-27 |
| IL288395A (en) | 2022-01-01 |
| CO2021017981A2 (es) | 2022-04-19 |
| CA3142340A1 (en) | 2020-12-03 |
| SG11202112952SA (en) | 2021-12-30 |
| JP2022534989A (ja) | 2022-08-04 |
| CR20210670A (es) | 2022-02-11 |
| WO2020243376A1 (en) | 2020-12-03 |
| TW202110841A (zh) | 2021-03-16 |
| MA56050A (fr) | 2022-04-06 |
| BR112021023825A2 (pt) | 2022-02-08 |
| JOP20210317A1 (ar) | 2023-01-30 |
| US20220251081A1 (en) | 2022-08-11 |
| EP3976611A1 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220387A1 (es) | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer | |
| CL2021001722A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| CL2021001721A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
| CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
| AR067505A1 (es) | Derivados de pirimidinil-piridazinona | |
| EA202190006A1 (ru) | Пуриноновые соединения и их применение при лечении рака | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR050694A1 (es) | Dihidropteridinonas para el tratamiento de enfermedades oncologicas | |
| CR20180172A (es) | Derivados de 8-[6-[3-(amino) propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| GT200900007A (es) | Derivados de purina como agonistas de a2a | |
| CL2023002635A1 (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1 | |
| UY29414A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| CL2023002362A1 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CL2023000837A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| CL2023000838A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| ECSP045477A (es) | COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS. | |
| UY28647A1 (es) | Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos | |
| AR132890A1 (es) | Aminas bicíclicas como inhibidores de cdk2 | |
| BR112022005558A2 (pt) | Compostos farmacêuticos |